1 178

Cited 2 times in

The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis

Authors
 Hee-Jin Park  ;  Min-Chan Park  ;  Yong-Beom Park  ;  Soo-Kon Lee  ;  Sang-Won Lee 
Citation
 RHEUMATOLOGY INTERNATIONAL, Vol.34(6) : 833-840, 2014 
Journal Title
 RHEUMATOLOGY INTERNATIONAL 
ISSN
 0172-8172 
Issue Date
2014
MeSH
Acute Kidney Injury/chemically induced* ; Adult ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects* ; Antirheumatic Agents/adverse effects* ; Arthritis, Rheumatoid/drug therapy* ; Asymptomatic Diseases ; Chemical and Drug Induced Liver Injury/etiology* ; Cohort Studies ; Drug Therapy, Combination/adverse effects ; Elasticity Imaging Techniques ; Female ; Humans ; Liver/diagnostic imaging ; Male ; Methotrexate/adverse effects* ; Middle Aged ; Odds Ratio ; Prospective Studies ; Thiazines/adverse effects* ; Thiazoles/adverse effects*
Keywords
Meloxicam ; Methotrexate ; Kidney ; Liver ; Damage
Abstract
We investigated whether the concomitant use of meloxicam and methotrexate might induce kidney and liver damages in patients with rheumatoid arthritis (RA). We enrolled 101 RA patients with normal kidney and liver functions taking meloxicam and methotrexate concomitantly for more than 6 months. Blood and urine tests were performed. Estimated glomerular filtration rate (eGFR) and liver stiffness measurement (LSM) were used for evaluating silent kidney and liver damages. Ultrasonography was also performed to exclude structural abnormalities. We adopted 90 mL/min/1.73 mm2 and 5.3 kPa as the cutoff for an abnormal eGFR and LSM. The mean age (85 women) was 51.9 years. The mean eGFR was 97.0 mL/min/1.73 m2 and the mean LSM was 4.7 kPa. The mean weekly dose of methotrexate was 13.4 mg. The mean weekly dose of methotrexate did not correlate with eGFR or LSM. Neither the cumulative dose of meloxicam or methotrexate nor the mean weekly dose of methotrexate showed the significant odds ratio or relative risk for abnormal eGFR and LSM values. The use of higher-dose MTX, above 15 mg per week, with meloxicam did not significantly increase the risk for abnormal LSM and eGFR (RR = 2.042, p = 0.185; RR = 0.473, p = 0.218). The concomitant use of meloxicam and MTX did not clearly increase the risk of silent kidney or liver damage in RA patients with normal laboratory results taking MTX and meloxicam concurrently for over 6 months.
Full Text
http://link.springer.com/article/10.1007%2Fs00296-013-2920-z
DOI
10.1007/s00296-013-2920-z
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Min Chan(박민찬) ORCID logo https://orcid.org/0000-0003-1189-7637
Park, Yong Beom(박용범)
Park, Hee Jin(박희진)
Lee, Sang Won(이상원) ORCID logo https://orcid.org/0000-0002-8038-3341
Lee, Soo Kon(이수곤)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98764
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse